Rethinking ovarian cancer III: the past decade and future directions

IF 60.7 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2026-04-13 DOI:10.1038/s41568-026-00916-0

Frances R. Balkwill, Céline M. Laumont, Nikki Burdett, Olivia Le Saux, Dale W. Garsed, Whitney R. Grither, Anke M. Nijhuis, Maria S. Recouvreux, Ziqi Kang, Rugang Zhang, Katherine B. Chiappinelli, Jason S. Lee, Denarda Dangaj Laniti, Iain McNeish, Ahmed A. Ahmed, Robert Rottapel, Jose R. Conejo-Garcia, Kunle Odunsi, Paul D. P. Pharoah, Dmitriy Zamarin, Charles A. Ishak, Christina Fotopoulou, Ronald J. Buckanovich, Intidhar Labidi-Galy, James D. Brenton, Ernst Lengyel, David P. Cook, Sophia H. L. George, Stephanie Lheureux, Ronny Drapkin, Kenneth P. Nephew, Sarah Adams, Shailja Pathania, Brad H. Nelson, Anniina Färkkilä, Katherine Fuh, Benjamin G. Neel, David D. Bowtell

{"title":"Rethinking ovarian cancer III: the past decade and future directions","authors":"Frances R. Balkwill, Céline M. Laumont, Nikki Burdett, Olivia Le Saux, Dale W. Garsed, Whitney R. Grither, Anke M. Nijhuis, Maria S. Recouvreux, Ziqi Kang, Rugang Zhang, Katherine B. Chiappinelli, Jason S. Lee, Denarda Dangaj Laniti, Iain McNeish, Ahmed A. Ahmed, Robert Rottapel, Jose R. Conejo-Garcia, Kunle Odunsi, Paul D. P. Pharoah, Dmitriy Zamarin, Charles A. Ishak, Christina Fotopoulou, Ronald J. Buckanovich, Intidhar Labidi-Galy, James D. Brenton, Ernst Lengyel, David P. Cook, Sophia H. L. George, Stephanie Lheureux, Ronny Drapkin, Kenneth P. Nephew, Sarah Adams, Shailja Pathania, Brad H. Nelson, Anniina Färkkilä, Katherine Fuh, Benjamin G. Neel, David D. Bowtell","doi":"10.1038/s41568-026-00916-0","DOIUrl":null,"url":null,"abstract":"Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead. In this Expert Recommendation, Bowtell and colleagues outline progress made over the last decade in the research and treatment of high-grade serous carcinoma as well as current challenges and research priorities for the coming years to reduce incidence and improve patient outcomes.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"26 6","pages":"452-471"},"PeriodicalIF":60.7000,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41568-026-00916-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead. In this Expert Recommendation, Bowtell and colleagues outline progress made over the last decade in the research and treatment of high-grade serous carcinoma as well as current challenges and research priorities for the coming years to reduce incidence and improve patient outcomes.

Abstract Image

查看原文本刊更多论文

重新思考卵巢癌III：过去的十年和未来的方向。

大约80%的卵巢癌死亡是由于高级别浆液性癌（HGSC），它在所有癌症类型中BRCA1或BRCA2 （BRCA1/BRCA2）突变比例最高，是一种染色体高度不稳定的疾病。尽管引入靶向治疗使一些HGSC患者受益，并且手术进展，但只有50%的患者存活超过5年，只有30%的无BRCA1/BRCA2突变的晚期疾病患者存活超过5年。本专家建议基于2024年10月由卵巢癌行动组织主办的第15届海伦·哈里斯纪念信托国际卵巢癌论坛上新兴和领先卵巢癌研究人员之间的讨论。会议审议了过去十年来在HGSC研究和治疗方面取得的进展、当前的挑战、预防、早期发现和治疗方面的新兴技术以及未来几年的研究重点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.